AEF0217 in Participants With Down Syndrome
A legfontosabb adatok
- Ki végzi
- Aelis Farma
- Hol
- Bologna, Rome és Troina (Olaszország)Mind a 3 helyszín megnézéseMég 2 másik országban, 7 helyszínen
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 188 fő, tervezett
- Kezdés
- 2025. dec. 22.
- Várható befejezés
- 2027. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 4 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- AEF0217 100 µg
- AEF0217 300 µg
- Placebo
- A regiszteradat frissítve
- 2026. április 8.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for teenagers and young adults with Down syndrome. It tests whether AEF0217 helps with daily life skills, compared with a placebo (dummy treatment).
- Életkor
- 16 to 32 years
- Nem
- Males and females
- A betegség stádiuma
- Down syndrome (full trisomy 21 or translocation). IQ above 35 up to 70 on the Leiter-3 test. People must walk on their own, see and hear well enough for the tests, and mostly understand and speak for themselves. BMI from 18.0 to 35 kg/m2. A parent or caregiver must come to all visits.
- Korábbi kezelés
- No 1st generation neuroleptic drugs now or in the 3 months before the start. No benzodiazepines now or in the 4 weeks before the first tests. No EGCG products (such as green tea capsules) in the last 4 weeks. No other trial drug, including AEF0217, in the last 3 months.
- Biomarker vagy leletérték
- Down syndrome confirmed by a chromosome test (karyotyping).
A részvétel fő kizáró okai
- Mosaic Down syndrome or Down Syndrome Regression Disorder (DSRD)
- Pregnant or breastfeeding
- Epilepsy now, or a past history of seizures, severe head injury or brain infection
- Signs of early dementia, or a serious mental health problem that dominates the person's health
- Severe obstructive sleep apnoea, or self-harm, suicide attempts or suicidal thoughts in the past 12 months
A regiszter feltételei, szó szerint
Mind a 36 feltétel megnézéseKevesebb
Ki vehet részt
- 1. Male and female. For males: Throughout the trial and until the end of the trial, male participants should refrain from donating sperm and, if sexually active, use double-barrier contraceptive methods (i.e., male condoms and spermicide), or the female partner must use the same highly effective contraceptive methods as female trial participants ; For females: Female participants of childbearing potential, defined as having a menstrual cycle that is confirmed prior to enrolment, must use highly effective contraception throughout the trial and until 3 months after the last dose of the trial intervention, be sexually abstinent, or have a vasectomized partner
- 2. Age ≥16 to ≤32years
- 3. BMI ≥18.0 and ≤35 kg/m2
- 4. Clinical diagnosis of Down syndrome (full trisomy 21 or translocations) documented by chromosomal analysis (karyotyping)
- 5. Must be independently mobile and have sufficient vision and hearing to participate in the trial evaluations
- 6. IQ >35-70 measured with Leiter-3. Individuals with IQ from >35 to <40 must have adequate cognitive and behavioural abilities according to the judgment of the principal investigator
- 7. VCI of WISC-V language test score >4, based on mental age (estimated via IQ)
- 8.Must be able to understand most of the time and to express if he/she does not understand to the extent that he/she can accept the trial procedures. Must not use other forms of communication, signs, symbol boards, or devices as his/her primary form of communication
- 9. Must have a parent or other reliable caregiver who agrees to accompany the participant to all clinic visits, provide information about the participant as required by the protocol, and ensure compliance with the medication schedule and protocol requirements
- 10.The parent or caregiver must be a constant and reliable informant with sufficient contact with the participant to have detailed knowledge of the participant's adaptive functioning to be able to answer accurately the questions asked by a neuropsychologist at the assessments
- 11. Vital signs, ECG , and safety laboratory3 parameters must be without clinically relevant abnormalities as per the judgement of the investigator, except for:; Stable type 1 or 2 diabetes provided the participant is monitored regularly prior to and during the trial to ensure adequate glucose control; Hypothyroidism controlled by treatment so that the participant is euthyroid and T4 stable (range 77-155 nmol/L) for at least 6 weeks prior to randomization. Fluctuations in TSH up to a maximum of 10 mIU/L are allowed
- 12. a. Assent by the participant and consent by the legally authorized representative(s) on behalf of the participant or b. Consent by the participant in situations where consent rather than assent can be provided by the participant
- 13. Informed consent by the participant's caregiver to take on the obligations of the caregiver in this trial
Ki nem vehet részt
- 4. Clinically relevant obstructive pulmonary disease or asthma that is untreated. Patients well-controlled by treatment (inhalation or oral) for at least 6 weeks prior to screening may be included if considered safe by the investigator
- 10. Participants with secondary psychiatric disorders including conduct disorders, attention deficit hyperactivity disorder, depressive disorders, anxiety disorders, and others that: 1) dominate the overall clinical condition according to the investigator's assessment; and/or 2) are not stabilized by medical or behavioural treatments, a stabilized treatment being defined as a stable therapeutic regimen and dose for the 3 months prior to randomization; and/or 3) the type of pharmacological treatment is on the list of drugs that are prohibited
- 13. Positive urine test for alcohol and drugs of abuse at screening and prior to first dosing
- 15. A history of intentional self-harm or suicide attempts brought on by suicidal thoughts. Suicidal ideation in the 12 months before screening, even if there was no suicide attempt or intentional self-harm. Assessed using 3 distinct questions about suicidal behaviour, suicidal ideation, and any self-harming actions
- 17. Clinically significant illness, such as active infections, within 2 weeks prior to randomization, according to the investigator's judgment
- 19. Any additional clinically significant concomitant disease, condition, or screening result that, in the investigator's opinion, could endanger the participant's safety, interfere with trial conduct and related procedures, or influence how the trial results are interpreted
- 20. Treatment with 1st generation neuroleptic drugs currently or within 3 months prior to randomization and benzodiazepines currently or in the 4 weeks prior to baseline assessments
- 21. Intake of products containing EGCG (e.g., TEAVIGO, Mega Green Tea Capsules Life Extension, or Font-UP Grand Fontaine Laboratories) currently or during the last 4 weeks prior to the baseline assessments
- 22. Treatment with medications or very regular consumption of fruits (i.e., pomelo/grapefruit) or natural remedies (i.e., hypericum preparations) known to strongly or moderately induce or inhibit CYP3A4/5 P450 isozymes
- 23. Administration of an investigational medicinal product, including AEF0217, within the last 3 months prior to randomization
- 1. Pregnant or nursing female. Down syndrome
- 2. Mosaic Down syndrome or Down Syndrome Regression Disorder (DSRD). Medical history and clinical status
- 3. Active or clinically relevant conditions that could, in the investigator's judgment, affect absorption, distribution, or metabolism of the trial medication (e.g., inflammatory bowel disease, gastric or duodenal ulcers or severe lactose intolerance); controlled celiac disease is allowed
- 6. Recent (≤1 year) or ongoing haematologic or oncologic disorders (mild anaemia is allowed)
- 7. History of infantile spasms/convulsions/epilepsy, severe head trauma or central nervous system infections (e.g., meningitis), except for isolated events of febrile seizures more than 8 years ago
- 8. Clinically relevant unstable gastrointestinal, renal, hepatic, endocrine (including metabolic syndrome), or cardiovascular system disease as per the investigator's judgement
- 9. Any prevailing psychiatric disorder diagnosed using the DSM-5 that dominates a person's overall clinical condition outside of Down syndrome. If symptoms consistent with a diagnosis of psychiatric illness are detected during the screening assessment (NPI-Q) and considered as dominating, the investigator may request a psychiatric evaluation. If necessary, a consultant psychiatrist will be responsible for the final diagnosis, as this is not the investigator's responsibility
- 11. Symptoms of early dementia confirmed by the NTG-EDSD
- 12. Substance use disorder as defined by the DSM-5
- 14. Current diagnosis of epilepsy
- 16. Known hypersensitivity to AEF0217 or fructose intolerance
- 18. Any current life-threatening disease
- 5. Known severe obstructive sleep apnoea or if the investigator thinks that the person should be referred for a diagnosis/treatment of obstructive sleep apnoea
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 16 és 32 év között vagy?
Helyszínek itt: Olaszország
Még 2 másik országban, 7 helyszínen
- Azienda Unita Sanitaria Locale Di BolognaBologna, OlaszországRésztvevőt keres
- Fondazione Policlinico Universitario Agostino Gemelli IRCCSRome, OlaszországRésztvevőt keres
- Associazione Oasi Maria S.S.OnlusTroina, OlaszországRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this clinical trial is to identify if AEF0217 show an improvement in adaptive behaviors (daily life activities) in adults and older adolescents with Down Syndrome. It will also learn about the safety of AEF0217.
A teljes eredeti leírásKevesebb
The main questions it aims to answer are:
* Does AEF0217 improve the daily life activities of the participants after being administered daily for 24 weeks ? * Does AEF0217 improve fluid cognitive function (cognitive abilities that do not depend on prior knowledge) and the crystallised one (knowledge acquired through one's culture, including verbal ability and social knowledge), the quality of life and sleep of the participants after being administered daily for 24 weeks ? * What medical problems do participants have when taking AEF0217?
Researchers will compare 3 doses of AEF0217 to a placebo (a look-alike substance that contains no drug) to see if AEF0217 improves adaptative behaviours in people with Down Syndrome.
Participants will:
* Take AEF0217 or a placebo every day for 24 weeks * Visit the clinic 6 times with their caregiver for checkups, performing tests on a tablet and answering questionnaires. * Be called by phone at home 5 times to check that they are well.
A vizsgálat 4 csoportja
- AEF0217 0.1 mgA vizsgált kezelés
1 sachet of AEF0217 100µg + 1 sachet of Placebo
Kezelés: AEF0217 100 µg és Placebo
- AEF0217 0.2 mgA vizsgált kezelés
2 sachets of AEF0217 100µg
Kezelés: AEF0217 100 µg
- AEF0217 0.6 mgA vizsgált kezelés
2 sachets of AEF0217 300µg
Kezelés: AEF0217 300 µg
- PlaceboPlacebo, összehasonlításként
2 sachets of placebo
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase 2b Trial to Assess the Efficacy, Safety and Tolerability of AEF0217 for 24 Weeks in Adults and Older Adolescents With Down Syndrome.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Illeszkedési kérdések
- Forrás: NCT07334912: ki vehet részt
- A regiszteradat frissítve
- 2026. április 8.